Skip to main content
DAEWON PHARMACEUTICAL CO.,LTD logo

DAEWON PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 003220 ISIN · KR7003220001 KO Manufacturing
Open in API
Filings indexed 300 across all filing types
Latest filing 2025-12-16 Regulatory Filings
Country KR South Korea
Listing KO 003220

About DAEWON PHARMACEUTICAL CO.,LTD

https://www.daewonpharm.com/eng

Daewon Pharmaceutical Co., Ltd., established in 1958, is a pharmaceutical company focused on improving human health. The company specializes in the development and manufacturing of prescription drugs and finished pharmaceutical products. Its portfolio includes a range of medications such as antipyretics, analgesics, and treatments for respiratory and cardiovascular conditions. Daewon Pharmaceutical maintains a strong commitment to research and development, with a strategic focus on New Chemical Entities (NCE) and Incrementally Modified Drugs (IMD) to provide advanced healthcare solutions.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement from Daewon Pharmaceutical regarding the setting of a record date for the purpose of holding the 65th Annual General Meeting. It is a standard corporate disclosure regarding shareholder rights and meeting preparation, which falls under general regulatory announcements.
2025-12-16 Korean
투자판단관련주요경영사항 (DW4421의 제3상 임상시험(비미란성)계획 승인)
Regulatory Filings Classification · 95% confidence The document is a disclosure about a significant management decision related to investment judgment, specifically the approval of a Phase 3 clinical trial plan by the Korean Ministry of Food and Drug Safety (MFDS) for a drug under development. It includes details such as approval dates, clinical trial design, and risks related to the drug development process. The document is a regulatory announcement informing investors about a material event affecting the company, rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-28 Korean
투자판단관련주요경영사항 (DW4421의 제3상 임상시험(미란성)계획 승인)
Board/Management Information Classification · 90% confidence The document is titled '투자판단 관련 주요경영사항' which translates to 'Important Management Matters Related to Investment Decisions'. It details the approval of a Phase 3 clinical trial plan by the Korean Ministry of Food and Drug Safety (MFDS) for a drug DW4421. The content focuses on the clinical trial approval, its details, and investment cautionary notes. There is no financial data, no mention of financial results, no board or management changes, no voting results, no legal proceedings, no capital changes, and no report publication announcements. The document is an announcement of a significant management event related to investment decisions, specifically a regulatory approval impacting the company's business prospects. This fits best under 'Board/Management Information (MANG)' as it relates to important management decisions affecting investment judgment. The document length is short (1731 characters), and it is not a report or a report announcement but a disclosure of a significant management event. Therefore, the classification is MANG with high confidence.
2025-10-15 Korean
투자판단관련주요경영사항 (코대원플러스정 식품의약품안전처 국내 품목허가 승인)
Regulatory Filings Classification · 95% confidence The document is a short announcement (1272 characters) about the approval of a domestic product license by the Korean Ministry of Food and Drug Safety (MFDS) for a pharmaceutical product. It includes details such as the product name, approval date, and expected effects, but does not contain any financial data, financial statements, or detailed management discussion. It is an announcement of a significant corporate event related to investment judgment but not a financial report or regulatory filing of financial results. The document is not a report itself but an announcement of a corporate event relevant to investors. Given the content and length, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-09-29 Korean
[기재정정]투자판단관련주요경영사항 (코대원플러스정 식품의약품안전처 국내 품목허가 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewon Pharmaceutical regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically a correction report (정정신고) concerning a drug approval application (코대원플러스정 품목허가 신청). It details clinical trial results, efficacy, safety, and future plans. Since it is a formal regulatory disclosure of a material business event that does not fit into specific categories like earnings releases or board changes, it is classified as a Regulatory Filing (RNS).
2025-09-17 Korean
자기주식처분결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a '자기주식처분결과보고서' (Report on the Results of Disposal of Treasury Shares) filed with the Financial Supervisory Service (FSS) in South Korea. It details the disposal of treasury shares related to the issuance of exchangeable bonds. Since the document reports the actual execution/result of a share disposal transaction (buyback/disposal), it falls under the category of 'Transaction in Own Shares'.
2025-09-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.